Teresa Carvalho, MS, science writer —

Teresa holds her Master of Science in cell and molecular biology from Coimbra University, Portugal. She was a researcher and science communicator for several years at the Institute for Research and Innovation in Health in Oporto, Portugal. From 2013, she has held a fellowship working with Pulmonary Hypertension Europe as a patient advocate, social media/website manager, public relations officer, and translator. Her work has been focused on providing patients access to treatments, raising awareness for pulmonary hypertension, and promoting patient empowerment.

Articles by Teresa Carvalho

MSAA Is ‘Improving Lives Through Art’

The Multiple Sclerosis Association of America (MSAA) is inviting people to participate in its Improving Lives Through Art Series, a cycle of virtual fundraising events starting Sept. 14. The kick-off event of this four-part fall series is a virtual follow-along painting experience. Tickets can be purchased here…

Safety Board Says Phase 2 Temelimab Trial Should Move Forward

A Phase 2a clinical trial evaluating GeNeuro‘s investigational antibody temelimab as a treatment for relapsing multiple sclerosis (MS) should continue as planned, without modifications. That’s the recommendation of a Drug Safety Monitoring Board, an independent committee of clinical research experts, which was evaluating the trial of the…

Online Art Auction Supports National MS Society

An online auction event supporting the National Multiple Sclerosis Society  is is running through Feb. 13 on Facebook. Organized by The Dyeing Arts group, the fundraising auction features tie dye and handcraft art from several online communities. The event arose from a partnership between Lighthouse Outdoor Products…

New Study Will Assess Tysabri Effects on MS Cognitive Fatigue

Researchers from the Kessler Foundation will launch a new study investigating the effects of Tysabri (natalizumab) on cognitive fatigue — the type of fatigue that happens after strong mental concentration, such as in problem-solving — in people with relapsing-remitting multiple sclerosis (RRMS). Cognitive fatigue, which is very…

Tysabri Superior to Gilenya at Easing Activity in RRMS, Study Reports

Treatment with Tysabri (natalizumab) was more effective than Gilenya (fingolimod) in helping people with relapsing–remitting multiple sclerosis (RRMS) achieve no evidence of disease activity, a head-to-head study suggested. The study, “BEST-MS: A prospective head-to-head comparative study of natalizumab and fingolimod in active relapsing MS,” was…

Dancing Doodle

Did you know some of the news and columns on Multiple Sclerosis News Today are recorded and available for listening on SoundCloud? These audio news stories give our readers an alternative option for accessing information important for them.

Listen Here